Ming-tao Liu, Xiuxiu Wang, Hui Li
Sep 4, 2019
Citations
0
Influential Citations
13
Citations
Journal
Thoracic Cancer
Abstract
The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non‐small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR‐2) and has shown good efficacy in a variety of malignancies, but the drug resistance is fast in single drug therapy.